Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
In recent times, the market size for chemotherapy-induced nausea and vomiting (cinv) has shown significant growth. It is predicted to expand from $2.92 billion in 2024 to $3.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historic growth phase can be attributed to factors such as an increase in the use of chemotherapy, the enhancement of antiemetic agents, clinical guidelines, and patient advocacy.
The market size of chemotherapy-induced nausea and vomiting (CINV) is predicted to witness substantial expansion in the upcoming years, reaching $4.19 billion in 2029 with a compound annual growth rate (CAGR) of 7.5%. This growth in the forecast era can largely be attributed to factors such as customised medicine, advancements in antiemetic drugs, telemedicine, remote patient monitoring, and health fairness initiatives. Notable trends anticipated within the forecast timeframe involve combination antiemetic treatments, supportive care provisions, virtual health technology, and survivorship care.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What Drivers Are Accelerating Expansion Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The continuous rise in cancer occurrences is predicted to stimulate the growth of the market for chemotherapy-induced nausea and vomiting (CINV). Cancer is a condition where body cells multiply uncontrollably and spread throughout the body. As the number of cancer cases escalates, there’s a heightened enthusiasm to formulate more precise and efficacious anti-emetic therapies to mitigate CINV, an unpleasant aftermath of chemotherapy. This increased emphasis on managing CINV has resulted in progress in comprehending its core causes and creating innovative treatments. For instance, in January 2023, as per the American Cancer Society (ACS), a volunteer health organization based in the US with a mission to eliminate cancer, roughly 5,370 new cancer cases and about 1,670 cancer-related deaths are expected daily, totaling 1.9 million and 609,820 respectively for the year in the United States. Consequently, the intensifying occurrence of cancer is anticipated to fuel the market for chemotherapy-induced nausea and vomiting (CINV).
What Are The Primary Segmentation Parameters In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
2) By Oral: Tablets; Capsules; Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches
How Are Industry Trends Steering The Expansion Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Key players in the market of chemotherapy-induced nausea and vomiting (CINV) are striving to gain a competitive edge through the invention of new products like the fixed intravenous antiemetic. This refers to a set dosage of medication, administered via an IV, that is used to prevent or manage nausea and vomiting typically occurring after chemotherapy or surgery. A case in point is Glenmark Pharmaceuticals Limited, an Indian pharmaceuticals, generics, and over-the-counter (OTC) products manufacturer, which launched AKYNZEO I.V., the first-ever fixed intravenous antiemetic combination, in India in January 2023. This product, a blend of netupitant and palonosetron, is aimed at managing both the initial and delayed stages of nausea and vomiting. It allows for convenience with a single dose, better complete response rates, and an improved quality of life for cancer patients, showing significant benefits for patients undergoing highly emetogenic chemotherapy, as per clinical research.
Which Players Are Shaping The Competitive Landscape Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025
Chemotherapy Induced Anemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model